# CRyoAblation vs AntiaRrhythmic Drugs for Persistent Atrial Fibrillation Trial

Study · id `cardio:ct-nct03716934` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03716934](<https://clinicaltrials.gov/study/NCT03716934>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03716934

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 196 participants.

## Technical summary

Registry record NCT03716934. Randomized; single masking; primary purpose treatment. Start 2018-06-27 (actual); primary completion 2022-04-18 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 196 participants (enrolled count; ClinicalTrials.gov record NCT03716934, source copy `cardio:ctgov-nct03716934-2025-09-15`, retrieved 2026-10-26)
- Started: 2018-06-27 (actual) (ClinicalTrials.gov record NCT03716934, source copy `cardio:ctgov-nct03716934-2025-09-15`, retrieved 2026-10-26)
- Primary completion: 2022-04-18 (actual) (ClinicalTrials.gov record NCT03716934, source copy `cardio:ctgov-nct03716934-2025-09-15`, retrieved 2026-10-26)
- Completion: 2022-04-18 (actual) (ClinicalTrials.gov record NCT03716934, source copy `cardio:ctgov-nct03716934-2025-09-15`, retrieved 2026-10-26)
- Countries: Spain (ClinicalTrials.gov record NCT03716934, source copy `cardio:ctgov-nct03716934-2025-09-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03716934-2025-09-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: CRyoAblation vs AntiaRrhythmic Drugs for Persistent Atrial Fibrillation Trial
- Acronym: craft
- Condition: Atrial Fibrillation
- Intervention (Device): Arctic Front Advance® balloon catheter
- Intervention (Drug): Antiarrhythmic drug
- Intervention (Device): Confirm RX heart monitor® (Abbott)
- Lead sponsor: Hospital San Carlos, Madrid
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Hospital San Carlos, Madrid (`cardio:org-hospital-san-carlos-madrid`)

## Provenance

Content hash: d70a403757f9e176ac9dd8e688c9cae6576f133bc650cfb9ff456b1107ba71ee
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
